论文部分内容阅读
新生血管生成在肿瘤的发生、发展及转移中起重要作用,且抗血管生成治疗取得了令人满意的效果。抗血管生成药物的研究得到人们的关注。反应停在20世纪50年代曾作为镇静药、止吐药使用,因其有很强的致畸作用而被市场淘汰,后发现其有免疫调节作用被用于治疗麻风、红斑狼疮、宿主抗移植物排斥反应等。随后的研究认为,其致畸作用可能与抗血管生成有关,从而用于治疗实体瘤及血液系统肿瘤。本文就反应停的抗肿瘤作用研究进展作一综述。
Neovascularization plays an important role in tumorigenesis, development and metastasis, and anti-angiogenic therapy has achieved satisfactory results. The research of antiangiogenic drugs has drawn people’s attention. The reaction stopped in the 1950s as a sedative, antiemetic drugs, because of its strong teratogenic effect was eliminated by the market and found that its immune regulatory role is used to treat leprosy, lupus, host anti-transplantation Exclusion reaction. Subsequent studies suggest that teratogenic effects may be related to anti-angiogenesis, which is used to treat solid tumors and hematological tumors. This article reviews the anti-tumor effects of the reaction to stop the progress made.